01 May 2026
Pure Global: Brazil's AI MedTech Maze - Cracking ANVISA's New Software Rules
LATAM MedTech Insights
About
Brazil's health regulatory agency, ANVISA, has just released a groundbreaking new framework for Software as a Medical Device (SaMD), creating significant new challenges for global MedTech innovators. This update introduces stricter requirements for clinical data and cybersecurity, tailored specifically to the Brazilian context.
This policy shift is forcing international companies to rethink their market entry strategies, as regulatory dossiers approved in other major markets may no longer be adequate. Imagine your AI-powered diagnostic tool, which has already received CE marking, being rejected by ANVISA because its validation data doesn't reflect Brazil's diverse population and its data servers aren't localized. This is the new reality, where overlooking local nuances can lead to costly delays and missed opportunities.
Key Takeaways:
- What specific cybersecurity protocols are now mandatory under ANVISA's new SaMD resolution?
- How can you gather clinical data that meets the new requirements for representing the Brazilian population?
- Can your existing EU MDR or FDA documentation be leveraged, or do you need to start from scratch for Brazil?
- What are the common pitfalls when appointing a Brazil Registration Holder for a complex SaMD product?
- What are the new labeling requirements for AI-powered devices regarding transparency and performance?
- How does Brazil's General Data Protection Law, the LGPD, intersect with these new ANVISA regulations?
- Is it more strategic to partner with a local entity or establish a subsidiary to meet the new compliance demands?
Struggling to keep up with these changes? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Contact us for a strategic consultation at info@pureglobal.com or visit us at https://pureglobal.com.
This policy shift is forcing international companies to rethink their market entry strategies, as regulatory dossiers approved in other major markets may no longer be adequate. Imagine your AI-powered diagnostic tool, which has already received CE marking, being rejected by ANVISA because its validation data doesn't reflect Brazil's diverse population and its data servers aren't localized. This is the new reality, where overlooking local nuances can lead to costly delays and missed opportunities.
Key Takeaways:
- What specific cybersecurity protocols are now mandatory under ANVISA's new SaMD resolution?
- How can you gather clinical data that meets the new requirements for representing the Brazilian population?
- Can your existing EU MDR or FDA documentation be leveraged, or do you need to start from scratch for Brazil?
- What are the common pitfalls when appointing a Brazil Registration Holder for a complex SaMD product?
- What are the new labeling requirements for AI-powered devices regarding transparency and performance?
- How does Brazil's General Data Protection Law, the LGPD, intersect with these new ANVISA regulations?
- Is it more strategic to partner with a local entity or establish a subsidiary to meet the new compliance demands?
Struggling to keep up with these changes? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Contact us for a strategic consultation at info@pureglobal.com or visit us at https://pureglobal.com.